| Business Summary | | ID
Biomedical
Corporation
is
a
biotechnology
company
involved
in
gene-based
disease
identification
and
sub-unit
vaccines.
The
Company
is
developing
gene-based
disease
identification
assays
(tests
for
a
particular
substance)
using
its
proprietary
gene-detection
system
known
as
Cycling
Probe
Technology
(CPT).
Using
CPT,
the
Company
is
developing
a
gene-based
format
under
the
trade
name
Velogene.
The
Company's
first
product
on
the
market
is
the
Velogene
Rapid
MRSA
Identification
Assay
for
methicillin-resistant
Staphyloccus
aureus
(MRSA).
A
second
product
candidate,
the
Velogene
Rapid
VRE
Identification
Assay
for
Vancomycin-resistant
enterococcis
is
currently
in
pre-clinical
development.
Each
assay
uses
CPT
to
detect
the
genes
believed
to
be
responsible
for
antibiotic
resistance
in
these
organisms.
The
Company
has
three
subsidiaries,
ID
Vaccine
Corporation,
ID
Biomedical,
Inc.
and
ID
Financial
Corporation. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IDBE
is
engaged
in
the
development
of
sub-unit
vaccines
against
infectious
diseases
and
rapid
gene-based
disease
identification.
For
the
three
months
ended
3/31/01,
revenues
totaled
C$1.2
million,
up
from
C$180
thousand.
Net
loss
fell
42%
to
C$1
million.
Revenues
reflect
increased
licensing
payments
received
and
earned
interest
and
other
income.
Lower
loss
reflect
improved
margins
and
lower
interest
balances
on
convertible
debentures
and
capital
leasing
arrangements. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
1,327;
after
tax
earnings
were
-2,323. (Preliminary; reported in thousands of Canadian Dollars.) | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1999 Pay | |
| Richard Bastiani Chairman | -- | Anthony Holler CEO,
Director | $160K | Todd Patrick Pres, COO | 146K | Robert Bryan, Ph.D. VP-
R&D | 111K | Deborah Bowers Sec. | -- | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|